Pharmaceutical distributors deliver millions of medicines and healthcare products to providers nationwide — rain, snow or shine. Every day, hundreds of thousands of patients across the country depend on the uninterrupted delivery of prescription medicines, and pharmaceutical distributors work around the clock to ensure these products get to where they need to be, safely and efficiently. As winter marches on, with snowstorms and sub-zero temperatures in parts of the country, HDA member companies rise to the challenge of making sure vital medicines reach the people who need them, no matter what it takes.
Pharmaceutical distributors have a long history of bringing the newest advancements and technologies to their warehouses. Back in 1947, the National Wholesale Druggists’ Association (an early iteration of HDA) tapped Ohio State University marketing experts to reimagine an entirely new type of layout for wholesaler warehouses, which included longer aisles, moving belts, “and roller skates for order pickers.” While the roller skates never caught on, healthcare distributors’ commitment to harnessing innovation to develop facilities that safely and securely get prescription medicines and medical products to the patients who need them has only grown.
With a new year in full swing, HDA President and CEO John M. Gray looked ahead to the organization’s 2019 priorities (along with other industry association executives) as part of the Chain Drug Review “Pharmacy Outlook” feature.
The Verification Router Service (VRS) started off as an idea in 2015. In 2016, it was identified as a preferred option for compliance with the 2019 saleable returns requirement (along with sending data via EPCIS). Since 2017, HDA has been convening industry stakeholders to write business requirements for the VRS, later pulling in solution providers to help with the technical details and then facilitating the group that developed the documentation that exists today.
A new report by Avalere Health, "Trends in Opioid Use: History, Background, and Origins of the Epidemic," comes at a critical point in the broader discussion about opioid abuse and misuse, and provides important context around the clinical, regulatory and policy milestones that contributed to the public health epidemic and impacted the national response to the crisis.